New Drug Updates in Solid Tumors: PARP Inhibitors in Ovarian Cancer, Immunotherapeutics, and Other Agents

Therapies approved for solid tumors by the FDA from 2016 to 2017 have transformed the way clinicians practice medicine. Dr. Li from the University of New England College of Pharmacy provides the latest clinical trial data and insights on the emergence of new drug classes such as PARP inhibitors and...

Descripción completa

Detalles Bibliográficos
Autor principal: Li, Edward
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press 2018
Materias:
Meeting Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333551/
_version_ 1783387567293464576
author Li, Edward
author_facet Li, Edward
author_sort Li, Edward
collection PubMed
description Therapies approved for solid tumors by the FDA from 2016 to 2017 have transformed the way clinicians practice medicine. Dr. Li from the University of New England College of Pharmacy provides the latest clinical trial data and insights on the emergence of new drug classes such as PARP inhibitors and PD-1/PD-L1 inhibitors.
format Online
Article
Text
id pubmed-6333551
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Harborside Press
record_format MEDLINE/PubMed
spelling pubmed-63335512019-02-04 New Drug Updates in Solid Tumors: PARP Inhibitors in Ovarian Cancer, Immunotherapeutics, and Other Agents Li, Edward J Adv Pract Oncol Meeting Reports Therapies approved for solid tumors by the FDA from 2016 to 2017 have transformed the way clinicians practice medicine. Dr. Li from the University of New England College of Pharmacy provides the latest clinical trial data and insights on the emergence of new drug classes such as PARP inhibitors and PD-1/PD-L1 inhibitors. Harborside Press 2018-04 2018-04-01 /pmc/articles/PMC6333551/ Text en Copyright © 2018, Harborside Press http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited and is for non-commercial purposes.
spellingShingle Meeting Reports
Li, Edward
New Drug Updates in Solid Tumors: PARP Inhibitors in Ovarian Cancer, Immunotherapeutics, and Other Agents
title New Drug Updates in Solid Tumors: PARP Inhibitors in Ovarian Cancer, Immunotherapeutics, and Other Agents
title_full New Drug Updates in Solid Tumors: PARP Inhibitors in Ovarian Cancer, Immunotherapeutics, and Other Agents
title_fullStr New Drug Updates in Solid Tumors: PARP Inhibitors in Ovarian Cancer, Immunotherapeutics, and Other Agents
title_full_unstemmed New Drug Updates in Solid Tumors: PARP Inhibitors in Ovarian Cancer, Immunotherapeutics, and Other Agents
title_short New Drug Updates in Solid Tumors: PARP Inhibitors in Ovarian Cancer, Immunotherapeutics, and Other Agents
title_sort new drug updates in solid tumors: parp inhibitors in ovarian cancer, immunotherapeutics, and other agents
topic Meeting Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333551/
work_keys_str_mv AT liedward newdrugupdatesinsolidtumorsparpinhibitorsinovariancancerimmunotherapeuticsandotheragents

Ejemplares similares